Share on StockTwits

Stock analysts at Roth Capital increased their target price on shares of BioDelivery Sciences International (NASDAQ:BDSI) from $15.50 to $16.50 in a report issued on Monday. Roth Capital’s target price would suggest a potential upside of 26.34% from the company’s current price.

Shares of BioDelivery Sciences International (NASDAQ:BDSI) traded up 8.92% during mid-day trading on Monday, hitting $13.06. The stock had a trading volume of 6,989,670 shares. BioDelivery Sciences International has a 52 week low of $4.15 and a 52 week high of $14.38. The stock’s 50-day moving average is $10.93 and its 200-day moving average is $8.73. The company’s market cap is $632.7 million.

BioDelivery Sciences International (NASDAQ:BDSI) last released its earnings data on Friday, May 9th. The company reported ($0.11) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.15) by $0.04. The company had revenue of $20.69 million for the quarter, compared to the consensus estimate of $11.60 million. Analysts expect that BioDelivery Sciences International will post $-0.65 EPS for the current fiscal year.

Other equities research analysts have also recently issued reports about the stock. Analysts at Ladenburg Thalmann raised their price target on shares of BioDelivery Sciences International to $18.00 in a research note on Monday, June 9th. They now have a “buy” rating on the stock. Separately, analysts at Laidlaw reiterated a “buy” rating on shares of BioDelivery Sciences International in a research note on Monday, June 9th. They now have a $15.00 price target on the stock. Finally, analysts at William Blair reiterated an “outperform” rating on shares of BioDelivery Sciences International in a research note on Monday, June 9th. They now have a $23.00 price target on the stock. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $19.42.

BioDelivery Sciences International, Inc (NASDAQ:BDSI) is a specialty pharmaceutical company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.